Flamel Technologies SA (FLML) is a Medical Drugs industry stock that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on FLML’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Flamel Technologies could be a solid choice for investors.
Current Quarter Estimates for FLML
In the past 30 days, 1 estimate has gone higher for Flamel Technologies while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 12 cents a share 30 days ago, to a loss of 10 cents today, a move of 16.7%.
Current Year Estimates for FLML
Meanwhile, Flamel Technologies’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no lower estimate. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.79 per share 30 days ago to a loss of $1.51 per share today, an increase of 15.6%.
Bottom Line
The stock has also started to move higher lately, adding 29.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment